No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
AU Stock MarketDetailed Quotes
VBLD Vanguard Global Infrastructure ETF
- 64.450
- +0.230+0.36%
20min DelayTrading Jul 19 14:50 AET
64.520High64.270Low
64.520High64.270Low4.71KVolume64.500Open64.220Pre Close303.43KTurnover66.55452wk High0.09%Turnover Ratio5.51MShares55.63352wk Low--EPS TTM355.36MFloat Cap66.554Historical High--P/E (Static)5.51MShs Float41.952Historical Low--EPS LYR0.39%Amplitude1.77Dividend TTM--P/B1Lot Size2.75%Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
A Closer Look at NextEra Energy's Options Market Dynamics
Financial giants have made a conspicuous bullish move on NextEra Energy. Our analysis of options history for NextEra Energy (NYSE:NEE) revealed 10 unusual trades.Delving into the details, we found 60%
U.S. Weekly Rail Traffic Rises 1.3% Year-over-year
Peering Into NextEra Energy's Recent Short Interest
NextEra Energy's (NYSE:NEE) short percent of float has risen 9.41% since its last report. The company recently reported that it has 38.16 million shares sold short, which is 1.86% of all regular
10 Industrials Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Union Pacific Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/17/2024 8.84% Stifel $267 → $265 Maintains Buy 07/08/2024 12.12% Bernstein $290 → $273 Maintains
Duke Energy Reaches Rate Settlement in Florida, Invests in Solar Projects
Comments
The trial of VB-601 may add value but hiring an advisor for strategic options and reporting losses indicate resource pressure and strategy shift, thus casting doubt on future performance.
Press Release: VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateMatthew Trudeau's appointment as CCO massively benefits VBL, given his extensive experience in leading commercial practices at different biotech firms. His expertise is expected to be crucial in preparing for the anticipated OVAL Phase 3 trial readout in the second half of 2022.
EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.
Read more